Cancer chronotherapy: Principles, applications, and perspectives

被引:184
作者
Mormont, MC
Levi, F
机构
[1] Hop Paul Brousse, INSERM, F-94800 Villejuif, France
[2] Hop Paul Brousse, Serv Cancerol, F-94800 Villejuif, France
关键词
circadian rhythms; chronopharmacology; chronotherapy; colorectal carcinoma; quality of life; survival;
D O I
10.1002/cncr.11040
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Cell physiology is regulated along the 24-hour timescale by a circathan clock, which is comprised of interconnected molecular loops involving at least nine genes. The cellular clocks are coordinated by the suprachiasmatic nucleus, a hypothalamic pacemaker that also helps the organism adjust to environmental cycles. The rest-activity rhythm is a reliable marker of the circadian system function in both rodents and humans. This circadian organization is responsible for predictable changes in the tolerability and efficacy of anticancer agents, and possibly also may be involved in tumor promotion or growth. METHODS. Expected least toxic times of chemotherapy were extrapolated from experimental models to human subjects with reference to the rest-activity cycle. The clinical relevance of the chronotherapy principle (i.e., treatment administration as a function of rhythms) has been investigated previously in randomized multicenter trials. RESULTS. in the current study, chronotherapeutic schedules were used to safely document activity of the combination of oxaliplatin, 5-fluorouracil, and leucovorin against metastatic colorectal carcinoma and to establish new medicosurgical management for this disease, and were reported to result in unprecedented long-term survival. CONCLUSIONS. Chronotherapy concepts appear to offer further potential to improve current cancer treatment options as well as to optimize the development of new anticancer or supportive agents.
引用
收藏
页码:155 / 169
页数:15
相关论文
共 99 条
[91]  
Tampellini M, 1998, CANCER RES, V58, P3896
[92]   Circadian oscillation of a mammalian homologue of the Drosophila period gene [J].
Tei, H ;
Okamura, H ;
Shigeyoshi, Y ;
Fukuhara, C ;
Ozawa, R ;
Hirose, M ;
Sakaki, Y .
NATURE, 1997, 389 (6650) :512-516
[93]  
THIBERVILLE L, 1994, CANCER CHEMOTH PHARM, V35, P64, DOI 10.1007/BF00686286
[94]   Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: Relationships with tumour marker antigens [J].
Touitou, Y ;
Bogdan, A ;
Levi, F ;
Benavides, M ;
Auzeby, A .
BRITISH JOURNAL OF CANCER, 1996, 74 (08) :1248-1252
[95]   RHYTHM ALTERATION IN PATIENTS WITH METASTATIC BREAST-CANCER AND POOR PROGNOSTIC FACTORS [J].
TOUITOU, Y ;
LEVI, F ;
BOGDAN, A ;
BENAVIDES, M ;
BAILLEUL, F ;
MISSET, JL .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1995, 121 (03) :181-188
[96]   MUTAGENESIS AND MAPPING OF A MOUSE GENE CLOCK, ESSENTIAL FOR CIRCADIAN BEHAVIOR [J].
VITATERNA, MH ;
KING, DP ;
CHANG, AM ;
KORNHAUSER, JM ;
LOWREY, PL ;
MCDONALD, JD ;
DOVE, WF ;
PINTO, LH ;
TUREK, FW ;
TAKAHASHI, JS .
SCIENCE, 1994, 264 (5159) :719-725
[97]  
VOUTILAINEN A, 1953, Acta Pathol Microbiol Scand Suppl, V99, P1
[98]  
ZAGULAMALLY ZW, 1979, CHRONOPHARMACOLOGY, P399
[99]  
ZHANG RW, 1993, CANCER RES, V53, P2816